Phase separation of BMAL1 converts circadian anti‑aging signaling into inflammaging when heterochromatin erodes

Dr. Hugo Mora (MD)· Mar 23, 2026

Mechanism: In aged cells, heterochromatin loss and increased acetylation cause BMAL1 to phase-separate into condensates, sequestering co-activators and promoting inflammation. Readout: Readout: Pharmacological rescue with a heterochromatin activator reduces BMAL1 condensation, decreases inflammation, and extends median lifespan.

Hypothesis

In aged tissues the circadian activator BMAL1 acquires aberrant phase‑separation properties due to loss of heterochromatin and increased lysine acetylation, turning it from a transcriptional activator into a sequestering scaffold that traps co‑activators (e.g., p300/CBP) and represses repair‑gene expression. This molecular switch explains why BMAL1 overexpression can become pro‑inflammatory in old organisms and predicts that restoring chromatin compaction or disrupting BMAL1’s intrinsically disordered region (IDR) will re‑establish its anti‑aging function even without altering BMAL1 levels.

Mechanistic rationale

The circadian clock drives rhythmic expression of NAMPT, sustaining NAD⁺‑dependent SIRT1 activity that deacetylates histones and clock proteins, linking metabolism to antioxidant defenses [1] [2].
BMAL1 also stabilizes heterochromatin independently of transcription, preserving genomic architecture in stem cells [3]
With age, heterochromatin declines and global acetylation rises, particularly at BMAL1‑binding sites, increasing the local concentration of acetyl‑lysine [4]
BMAL1 contains a low‑complexity IDR that mediates phase separation in vitro; acetylation enhances its propensity to form nuclear condensates [5]
When BMAL1 condenses, it sequesters transcriptional co‑activators and RNA‑polymerase II, reducing expression of DNA‑repair, autophagy, and senescence‑suppression genes while simultaneously promoting NFκB‑driven inflammatory transcripts [6]

Testable predictions

Imaging – In muscle and liver from 24‑month‑old mice, BMAL1 will form discrete nuclear foci that co‑localize with markers of heterochromatin loss (H3K9me3 low) and acetyl‑lysine, whereas young mice show diffuse nucleoplasmic BMAL1.
Genetic disruption – Knock‑in of acetylation‑resistant lysine‑to‑arginine mutations in BMAL1’s IDR (or deletion of the IDR) will reduce nuclear foci formation in old mice, restore rhythmic expression of SIRT1‑target genes (e.g., SOD2, LC3), and decrease NFκB‑driven cytokines (IL‑6, TNF‑α) without changing total BMAL1 protein.
Pharmacological rescue – Treatment with a heterochromatin‑inducing compound (e.g., SUV39H1 activator) in aged mice will diminish BMAL1 condensation, improve autophagic flux (LC3‑II/I ratio), and extend median lifespan relative to vehicle controls.
In vitro reconstitution – Purified BMAL1 IDR will form condensates at physiological concentrations only when incubated with acetylated histone peptides; adding a heterochromatin mimic (unmethylated H3K9 peptide) will inhibit condensation.

Falsifiability

If aged tissues show no increase in BMAL1 nuclear foci, or if disrupting BMAL1 phase separation fails to improve repair‑gene activity or inflammation, the hypothesis is refuted. Conversely, confirming any of the above predictions would support the idea that the circadian clock’s anti‑aging capacity is gated by its phase‑state, which is itself regulated by chromatin integrity.

Implications

This reframes the circadian system from a static firewall to a dynamic gatekeeper whose protective output depends on the biophysical state of its core components. Therapeutic strategies that combine chronotherapy with chromatin‑modulating agents—or that target IDR‑driven phase separation—could rejuvenate circadian function in aging and age‑related disease.

Hypothesis

Mechanistic rationale

The circadian clock drives rhythmic expression of NAMPT, sustaining NAD⁺‑dependent SIRT1 activity that deacetylates histones and clock proteins, linking metabolism to antioxidant defenses [1] [2].

BMAL1 also stabilizes heterochromatin independently of transcription, preserving genomic architecture in stem cells [3]

With age, heterochromatin declines and global acetylation rises, particularly at BMAL1‑binding sites, increasing the local concentration of acetyl‑lysine [4]

BMAL1 contains a low‑complexity IDR that mediates phase separation in vitro; acetylation enhances its propensity to form nuclear condensates [5]

When BMAL1 condenses, it sequesters transcriptional co‑activators and RNA‑polymerase II, reducing expression of DNA‑repair, autophagy, and senescence‑suppression genes while simultaneously promoting NFκB‑driven inflammatory transcripts [6]

Testable predictions

Imaging – In muscle and liver from 24‑month‑old mice, BMAL1 will form discrete nuclear foci that co‑localize with markers of heterochromatin loss (H3K9me3 low) and acetyl‑lysine, whereas young mice show diffuse nucleoplasmic BMAL1.

Genetic disruption – Knock‑in of acetylation‑resistant lysine‑to‑arginine mutations in BMAL1’s IDR (or deletion of the IDR) will reduce nuclear foci formation in old mice, restore rhythmic expression of SIRT1‑target genes (e.g., SOD2, LC3), and decrease NFκB‑driven cytokines (IL‑6, TNF‑α) without changing total BMAL1 protein.

Pharmacological rescue – Treatment with a heterochromatin‑inducing compound (e.g., SUV39H1 activator) in aged mice will diminish BMAL1 condensation, improve autophagic flux (LC3‑II/I ratio), and extend median lifespan relative to vehicle controls.

In vitro reconstitution – Purified BMAL1 IDR will form condensates at physiological concentrations only when incubated with acetylated histone peptides; adding a heterochromatin mimic (unmethylated H3K9 peptide) will inhibit condensation.

Falsifiability

Implications